Literature DB >> 10917893

Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship.

E Matsuura1, J Inagaki, H Kasahara, D Yamamoto, T Atsumi, K Kobayashi, K Kaihara, D Zhao, K Ichikawa, A Tsutsumi, T Yasuda, D A Triplett, T Koike.   

Abstract

Binding of beta(2)-glycoprotein I (beta(2)-GPI)-dependent anticardiolipin antibodies (aCL) derived from antiphospholipid syndrome (APS) is significantly reduced in aCL ELISA due to loss of the phospholipid (PL) binding property of beta(2)-GPI by plasmin treatment. In the present study, the treatment generated a nicked form of beta(2)-GPI and resulted in loss of antigenicity for the autoantibodies detected in ELISA, using an beta(2)-GPI directly adsorbed polyoxygenated carboxylated plate, the assay system of which was not related to PL binding. The nicked form bound to neither Cu(2+)-oxidized low-density lipoprotein (oxLDL) nor to beta(2)-GPI-specific lipid ligands isolated from oxLDL, the result being a complete loss of subsequent binding of anti-beta(2)-GPI autoantibodies. The conformational change in the nicked domain V was predicted from its intact structure determined by an X-ray analysis (implemented in Protein Data Bank: 1C1Z), molecular modeling and epitope mapping of a monoclonal anti-beta(2)-GPI antibody, i.e. Cof-18, which recognizes the related structure. The analysis revealed that novel hydrophobic and electrostatic interactions appeared in domain V after the cleavage, thereby affecting the PL binding of beta(2)-GPI. Such a conformational change may have important implications for exposure of cryptic epitopes located in the domains such as domain IV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10917893     DOI: 10.1093/intimm/12.8.1183

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9.

Authors:  Arnaud Dupuy D'Angeac; Ilias Stefas; Hubert Graafland; Frédéric De Lamotte; Marcel Rucheton; Caroline Palais; Anna-Karin Eriksson; Priscille Bosc; Caroline Rosé; Robert Chicheportiche
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

Authors:  Taro Sakai; Krishnakumar Balasubramanian; Sourindra Maiti; Jyotsna B Halder; Alan J Schroit
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

3.  Recombinant domain V of β2-glycoprotein I inhibits the formation of atherogenic oxLDL/β2-glycoprotein I complexes.

Authors:  Jingda Li; Yan Chi; Shuqian Liu; Le Wang; Renjun Wang; Xiaofei Han; Eiji Matsuura; Qingping Liu
Journal:  J Clin Immunol       Date:  2014-06-27       Impact factor: 8.317

Review 4.  The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS.

Authors:  Thomas McDonnell; Chris Wincup; Ina Buchholz; Charis Pericleous; Ian Giles; Vera Ripoll; Hannah Cohen; Mihaela Delcea; Anisur Rahman
Journal:  Blood Rev       Date:  2019-08-16       Impact factor: 10.626

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.